Cyclin-dependent kinase 9 messenger RNA (CDK9 mRNA)

Cyclin-dependent kinase 9 (CDK9) mRNA is the transcript that encodes the catalytic subunit of the Positive Transcription Elongation Factor b (P-TEFb) complex, a master regulator of transcriptional elongation (Source: UniProt P50750). By phosphorylating the C-terminal domain of RNA polymerase II, the protein product of this mRNA enables the synthesis of full-length transcripts for genes involved in cell survival and growth, such as MCL-1 and MYC (Source: PubMed, PMID: 29433130). In many cancers, including leukemias and various solid tumors, the CDK9 pathway is hyperactivated to maintain the expression of these short-lived anti-apoptotic factors, making the mRNA a strategic target for therapeutic intervention (Source: Nature Reviews Drug Discovery). Targeting the mRNA directly using antisense oligonucleotides (ASOs) or RNA interference (RNAi) allows for the depletion of the CDK9 protein pool, which can overcome resistance mechanisms associated with traditional small-molecule kinase inhibitors (Source: Molecular Cancer Therapeutics). This approach leads to a rapid decline in oncogenic protein levels and triggers apoptosis in malignant cells that are highly dependent on continuous transcriptional output (Source: Cell Death & Disease).

Other names

C-terminal domain kinase subunit mRNAPITALRE mRNACDC2L4 mRNACell division cycle 2-like protein 4 mRNATAK mRNA

Targeting CDK9 mRNA involves the use of sequence-specific nucleic acid therapeutics, such as antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs), to induce the degradation of the transcript. ASOs typically trigger RNase H-mediated cleavage of the mRNA, while siRNAs utilize the RNA-induced silencing complex (RISC) to achieve degradation. This depletion of the mRNA template prevents the translation of the CDK9 protein, thereby inhibiting the formation of the Positive Transcription Elongation Factor b (P-TEFb) complex and halting the transcription of downstream oncogenic and anti-apoptotic genes.